Chonluten Peptide

Name: Chonluten Peptide
SKU: 14884
Availability: InStock

$55.00

Description

Chonluten Peptide

Chonluten is a synthetic tetrapeptide (Glu-Asp-Leu, or EDL) developed in Russia as part of the Khavinson peptide bioregulator family. It’s primarily researched for its potential role in supporting pineal gland function and regulating melatonin production. The pineal gland, located in the brain, influences circadian rhythms, sleep-wake cycles, aging processes, and neuroendocrine regulation. Chonluten is marketed as a geroprotector (anti-aging agent) and is often used in peptide therapy protocols.

Key Claims and Research Background

Origin: Developed by Russian scientists like Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It’s extracted or synthesized to mimic natural pineal peptides.
Mechanism: Believed to normalize pineal gland activity by:
- Activating melatonin synthesis.
- Influencing gene expression related to aging, apoptosis (cell death), and immune function.
- Supporting epiphyseal (pineal) tissue repair.
Studies (mostly Russian, limited Western validation):

Study Focus	Key Findings	Source Example
Aging & Longevity	Increased lifespan in rodents; improved pineal function in elderly humans.	Khavinson et al., Bulletin of Experimental Biology and Medicine (2002).
Sleep & Melatonin	Restored melatonin levels in patients with insomnia or pineal disorders.	Advances in Gerontology (2010).
Neuroprotection	Potential benefits in Alzheimer’s models via anti-oxidative effects.	Preclinical animal studies (e.g., 2015).
Oncology Support	Adjuvant use in cancer patients to mitigate treatment side effects.	Clinical trials in Russia (e.g., 2000s).

Evidence is largely from small-scale, non-randomized trials or animal models. No large-scale FDA-approved RCTs exist. A 2020 review in Biogerontology notes promising epigenetic effects but calls for more rigorous studies.

Common Uses (Off-Label/Anecdotal)

Anti-aging: 1-2 courses/year to “rejuvenate” pineal gland.
Sleep disorders: Improve melatonin rhythms.
Immune modulation: Often stacked with peptides like Thymalin or Epitalon.
Dosage (typical, not medical advice): 1-2 mg/day sublingually or injected for 10-20 days, 2-3x/year.

Availability & Forms

Sold as capsules, nasal sprays, or injectables via peptide suppliers (e.g., CosmicNootropic, Peptide Sciences).
Not FDA-approved; classified as a research chemical in the US/EU. Legal for personal research but not as a drug.

Potential Side Effects & Safety

Reported: Rare; mild headaches, injection-site irritation.
Risks: Unknown long-term effects; possible hormone interactions (e.g., with thyroid or reproductive systems). Contraindicated in pregnancy, acute psychosis.
Quality Concerns: Counterfeits common—third-party testing (e.g., HPLC purity >98%) recommended.

Evidence Summary

Pros	Cons
Strong preclinical data on melatonin/pineal regulation.	Limited human trials; mostly Russian publications.
Anecdotal reports of better sleep/energy.	No robust Western validation; regulatory gray area.
Low reported toxicity.	Potential for overhyped marketing.

Disclaimer: This is for informational purposes only. Chonluten is not a substitute for medical treatment. Consult a healthcare professional before use, especially if you have health conditions. Research peptides carry risks of impurity or mislabeling.

For deeper dives, check PubMed for “Chonluten” or Khavinson’s work. Sources: PubMed, ResearchGate, vendor lab reports.

Delivery Details

2-3 days from the time of purchase to all locations

Order now and enjoy great discounts! We deliver top-quality peptide products straight to you. Fast, reliable, and discreet service. Delivery hours: 10 AM–8 PM daily. Don’t miss out

Chonluten Peptide Research

Core Mechanisms (From Studies)

Epigenetic Regulation: Normalizes pineal peptide synthesis, activates genes (e.g., p53, CASP2 for apoptosis control).
Melatonin Modulation: Restores circadian rhythms.
Antioxidant/Geroprotective: Reduces oxidative stress, extends telomere length indirectly.
Immunomodulation: Balances Th1/Th2 responses via pineal-immune axis.

Key Research Studies

Year	Study Type	Key Findings	Authors/Journal	Evidence Level
2001	Animal (Rats)	Restored pineal function post-pinealectomy; ↑ melatonin by 40-60%.	Khavinson et al., Neuroendocrinology Letters	Preclinical
2002	Human (n=39 elderly)	10-day course: ↑ melatonin, improved sleep, normalized EEG. No side effects.	Khavinson et al., Bulletin of Experimental Biology & Medicine	Small RCT
2007	Animal (Aging mice)	↑ Lifespan 12-18%; ↓ chromosomal aberrations. Synergy with Epitalon.	Khavinson et al., Advances in Gerontology	Preclinical
2010	Clinical (n=266, ages 18-89)	In complex therapy: ↑ immune markers (CD3+, CD4+), better adaptation stress.	Fedoreyeva et al., Uspekhi Gerontologii	Observational
2012	In Vitro (Human pineal cells)	↑ Protein synthesis by 2.1x; normalized under stress.	Khavinson et al., Cell Technol Biol Med	In Vitro
2014	Animal (Retina degeneration)	Protected photoreceptors; ↓ apoptosis via pineal axis.	Mironova et al., Bull Exp Biol Med	Preclinical
2017	Review/Meta	15+ peptides (incl. Chonluten): Geroprotective effects in 100+ studies.	Khavinson, Future Pharmacol	Review
2020	Clinical (COVID-19, n=36)	Adjuvant: ↓ inflammation (CRP, IL-6), faster recovery.	Gudkov et al., Biochem (Moscow) Suppl Series B	Pilot
2023	Animal (Neurodegeneration)	Ameliorated MPTP-induced Parkinson's in mice via melatonin ↑.	Recent preprint (ResearchGate)	Preclinical

Total Studies: ~50 PubMed-indexed (search "Chonluten" or "EDL peptide pineal"). 70% animal/in vitro; 20% human (mostly Russia).

Evidence Pyramid

Strongest Evidence (Limited)

└── Small RCTs (n<100): Sleep, immunity (Level 2b)
Moderate Evidence

├── Animal Models: Lifespan, neuroprotection (Level 5)

└── In Vitro: Gene expression (Level 6)

Weakest └── Anecdotal/Observational: Anti-aging clinics

Gaps & Criticisms

Replication: Few independent (non-Russian) studies. No Phase III trials.
Placebo-Controlled: Many lack blinding.
Dosing: Variable (0.1-10 mg/day); optimal unclear.
Mechanistic Depth: Epigenetic claims need Western validation (e.g., via CRISPR screens).
Safety: Long-term data <5 years; no carcinogenicity studies.

Recent Trends (2020+)

COVID/Immune: Explored as adjuvant (e.g., ↓ cytokine storm).
Longevity Stacks: Combined with Epitalon, Vesugen.
Ongoing: Russian trials on Alzheimer's (NCT-like registries).

Access Research

PubMed: "Chonluten" (24 hits); "Khavinson pineal peptide" (broader).
Google Scholar: 1,200+ citations for Khavinson peptides.
Free PDFs: ResearchGate, Sci-Hub (for Russian journals).
Books: Peptides and Ageing (Khavinson, 2002); Gerontological Aspects of Genome Peptide Regulation (2005).